Literature DB >> 33723657

Is there association between clinically relevant toxicities of pazopanib and sunitinib with the use of weak CYP3A4 and P-gp inhibitors?

Setayesh Sadeghi1, Mona Kargar2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33723657     DOI： 10.1007/s00228-021-03118-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

Review 1.  Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.

Authors:  C Resteghini; S Cavalieri; D Galbiati; R Granata; S Alfieri; C Bergamini; P Bossi; L Licitra; L D Locati
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2017-05-10       Impact factor: 4.690

Review 2.  Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.

Authors:  Matteo Santoni; Alessandro Conti; Francesco Massari; Giorgio Arnaldi; Roberto Iacovelli; Mimma Rizzo; Ugo De Giorgi; Laura Trementino; Giuseppe Procopio; Giampaolo Tortora; Stefano Cascinu
Journal:  Int J Cancer       Date:  2014-02-07       Impact factor: 7.396

3.  Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study.

Authors:  Djoeke de Wit; Nielka P van Erp; Jan den Hartigh; Ron Wolterbeek; Margret den Hollander-van Deursen; Mariëtte Labots; Henk-Jan Guchelaar; Henk M Verheul; Hans Gelderblom
Journal:  Ther Drug Monit       Date:  2015-06       Impact factor: 3.681

4.  Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors.

Authors:  Camille Azam; Pauline Claraz; Christine Chevreau; Camille Vinson; Ewa Cottura; Loïc Mourey; Damien Pouessel; Selena Guibaud; Olivia Pollet; Magali Le Goff; Catherine Bardies; Véronique Pelagatti; Jean Marie Canonge; Florent Puisset
Journal:  Eur J Clin Pharmacol       Date:  2020-01-13       Impact factor: 2.953

Review 5.  Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.

Authors:  Remy B Verheijen; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema; Neeltje Steeghs
Journal:  Clin Pharmacokinet       Date:  2017-09       Impact factor: 6.447
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.